Difference between revisions of "Nilotinib (Tasigna)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor of Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML. Nilotinib binds to the inactive conformation of the Abl kinase domain and stabilizes it.<ref name="insert">[ | + | Class/mechanism: Tyrosine kinase inhibitor of Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML. Nilotinib binds to the inactive conformation of the Abl kinase domain and stabilizes it.<ref name="insert">[https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tasigna.pdf Nilotinib (Tasigna) package insert]</ref><ref>[[Media:Nilotinib.pdf | Nilotinib (Tasigna) package insert (locally hosted backup)]]</ref><ref>[http://tasigna.com Tasigna manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 13: | Line 13: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tasigna.pdf Nilotinib (Tasigna) package insert]<ref name="insert"></ref> |
*[http://chemocare.com/bio/nilotinib.asp Nilotinib (Tasigna) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/nilotinib.asp Nilotinib (Tasigna) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/nilotinib.asp Nilotinib (Tasigna) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/nilotinib.asp Nilotinib (Tasigna) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/nilotinib-patient-drug-information Nilotinib (Tasigna) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/nilotinib-patient-drug-information Nilotinib (Tasigna) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/nilotinib-patient-drug-information Nilotinib (Tasigna) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/nilotinib-patient-drug-information Nilotinib (Tasigna) patient drug information (UpToDate)]</ref> | ||
Revision as of 06:09, 14 April 2017
General information
Class/mechanism: Tyrosine kinase inhibitor of Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML. Nilotinib binds to the inactive conformation of the Abl kinase domain and stabilizes it.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Chronic myelogenous leukemia
- Hypereosinophilic syndrome
- Systemic mastocytosis
Patient drug information
- Nilotinib (Tasigna) package insert[1]
- Nilotinib (Tasigna) patient drug information (Chemocare)[4]
- Nilotinib (Tasigna) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 10/29/2007: Granted FDA accelerated approval for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included Imatinib (Gleevec).
- 6/17/2010: New indication for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Also known as
AMN107